Tech Company Financing Transactions
ARS Pharmaceuticals Funding Round
On 9/1/2021, ARS Pharmaceuticals raised $55 million in Series D financing from SR One Capital Management, Deerfield Capital and RA Capital.
Transaction Overview
Company Name
Announced On
9/1/2021
Transaction Type
Venture Equity
Amount
$55,000,000
Round
Series D
Investors
SR One Capital Management (Lead Investor) (Rajeev Dadoo)
RA Capital (Peter Kolchinsky)
Proceeds Purpose
The company intends to use the funds to advance Neffy through approval, to support initial launch activities, and to evaluate it in clinical studies for additional indications.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3525 Del Mar Heights Rd. 855
San Diego, CA 92130
USA
San Diego, CA 92130
USA
Phone
Website
Email Address
Not Recorded
Overview
Our mission at ARS Pharmaceuticals is to provide at-risk patients and their families superior protection from severe allergic reactions. We are developing a product that patients and their caregivers can use without anxiety or hesitation, confident in both the product and the ability to administer it.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Richard Lowenthal
Chief Financial Officer
Dana McGowan
Chief Medical Officer
Sarina Tanimoto
Chief Scientific Officer
Robert Bell
VP - Bus. Development
Justin Chakma
VP - Operations
Brian Dorsey
Browse more venture capital transactions:
Prev: 8/31/2021: WHOOP venture capital transaction
Next: 9/1/2021: Gatik venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record all VC transactions involving tech companies. VC transactions reported here are derived from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs